Galmed Pharmaceuticals shares are trading lower. The company announced that results of its Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis has been published in Hepatology.
Portfolio Pulse from Benzinga Newsdesk
Galmed Pharmaceuticals' shares are declining following the publication of its Phase 3 trial results for Aramchol in patients with NASH and fibrosis in the journal Hepatology.
September 25, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Galmed Pharmaceuticals' stock is trading lower after the publication of its Phase 3 trial results for Aramchol in Hepatology. The results pertain to its use in patients with NASH and fibrosis.
The publication of Phase 3 trial results is a significant event for biotech companies, as it can influence investor perception and stock price. The decline in share price suggests that the market may have reacted negatively to the results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100